Related references
Note: Only part of the references are listed.Recognition determinants of broadly neutralizing human antibodies against dengue viruses
Alexander Rouvinski et al.
NATURE (2015)
Dengue E Protein Domain III-Based DNA Immunisation Induces Strong Antibody Responses to All Four Viral Serotypes
Monica Poggianella et al.
PLOS NEGLECTED TROPICAL DISEASES (2015)
Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial
Uzma N. Sarwar et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus
Wanwisa Dejnirattisai et al.
NATURE IMMUNOLOGY (2015)
Climate change and dengue: a critical and systematic review of quantitative modelling approaches
Suchithra Naish et al.
BMC INFECTIOUS DISEASES (2014)
Virus-Like Particle Secretion and Genotype-Dependent Immunogenicity of Dengue Virus Serotype 2 DNA Vaccine
Jedhan U. Galula et al.
JOURNAL OF VIROLOGY (2014)
Activity of the HMGB1-derived immunostimulatory peptide Hp91 resides in the helical C-terminal portion and is enhanced by dimerization
R. Saenz et al.
MOLECULAR IMMUNOLOGY (2014)
New Tags for Recombinant Protein Detection and O-Glycosylation Reporters
Gianluca Petris et al.
PLOS ONE (2014)
Characterization of the Ectodomain of the Envelope Protein of Dengue Virus Type 4: Expression, Membrane Association, Secretion and Particle Formation in the Absence of Precursor Membrane Protein
Szu-Chia Hsieh et al.
PLOS ONE (2014)
Induction of Neutralizing Antibody Response against Four Dengue Viruses in Mice by Intramuscular Electroporation of Tetravalent DNA Vaccines
Eakachai Prompetchara et al.
PLOS ONE (2014)
Chaperone fusion proteins aid entropy-driven maturation of class II viral fusion proteins
Peng Ge et al.
TRENDS IN MICROBIOLOGY (2014)
Relating structure to evolution in class II viral membrane fusion proteins
Yorgo Modis
CURRENT OPINION IN VIROLOGY (2014)
Structure of a Dengue Virus Envelope Protein Late-Stage Fusion Intermediate
Daryl E. Klein et al.
JOURNAL OF VIROLOGY (2013)
Pichia pastoris-Expressed Dengue 2 Envelope Forms Virus-Like Particles without Pre-Membrane Protein and Induces High Titer Neutralizing Antibodies
Shailendra Mani et al.
PLOS ONE (2013)
Burden of dengue fever is higher than previously thought
Anne Gulland
BMJ-BRITISH MEDICAL JOURNAL (2013)
Protection from Secondary Dengue Virus Infection in a Mouse Model Reveals the Role of Serotype Cross-Reactive B and T Cells
Simona Zompi et al.
JOURNAL OF IMMUNOLOGY (2012)
Mutagenesis of the DI/DIII Linker in Dengue Virus Envelope Protein Impairs Viral Particle Assembly
Melissanne de Wispelaere et al.
JOURNAL OF VIROLOGY (2012)
Novel AAV-based genetic vaccines encoding truncated dengue virus envelope proteins elicit humoral immune responses in mice
Xueling Li et al.
MICROBES AND INFECTION (2012)
CURRENT CONCEPTS Dengue
Cameron P. Simmons et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
C-Terminal Helical Domains of Dengue Virus Type 4 E Protein Affect the Expression/Stability of prM Protein and Conformation of prM and E Proteins
Wen-Yang Tsai et al.
PLOS ONE (2012)
Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo
Katherine L. Williams et al.
VIROLOGY (2012)
Analysis of Epitopes on Dengue Virus Envelope Protein Recognized by Monoclonal Antibodies and Polyclonal Human Sera by a High Throughput Assay
Hong-En Lin et al.
PLOS NEGLECTED TROPICAL DISEASES (2012)
Novel Strategies to Improve DNA Vaccine Immunogenicity
Cevayir Coban et al.
CURRENT GENE THERAPY (2011)
A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial
Julie E. Ledgerwood et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
DNA Vaccines against Dengue Virus Type 2 Based on Truncate Envelope Protein or Its Domain III
Adriana S. Azevedo et al.
PLOS ONE (2011)
A DNA vaccine candidate encoding the structural prM/E proteins elicits a strong immune response and protects mice against dengue-4 virus infection
Danielle Malta Lima et al.
VACCINE (2011)
Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial
Charmagne G. Beckett et al.
VACCINE (2011)
The development of recombinant subunit envelope-based against dengue virus induced disease
Beth-Ann G. Coller et al.
VACCINE (2011)
Amino acid changes within the E protein hinge region that affect dengue virus type 2 infectivity and fusion
Siritorn Butrapet et al.
VIROLOGY (2011)
The Human Antibody Response to Dengue Virus Infection
Wahala M. P. B. Wahala et al.
VIRUSES-BASEL (2011)
Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms
Alan L. Rothman
NATURE REVIEWS IMMUNOLOGY (2011)
In Vitro Reconstitution Reveals Key Intermediate States of Trimer Formation by the Dengue Virus Membrane Fusion Protein
Maofu Liao et al.
JOURNAL OF VIROLOGY (2010)
Structure and Function Analysis of Therapeutic Monoclonal Antibodies against Dengue Virus Type 2
Soila Sukupolvi-Petty et al.
JOURNAL OF VIROLOGY (2010)
A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation
Dorothy Beckett et al.
PROTEIN SCIENCE (2010)
Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans
Wanwisa Dejnirattisai et al.
SCIENCE (2010)
Domain-III FG loop of the dengue virus type 2 envelope protein is important for infection of mammalian cells and Aedes aegypti mosquitoes
Steven M. Erb et al.
VIROLOGY (2010)
Immature Dengue Virus: A Veiled Pathogen?
Izabela A. Rodenhuis-Zybert et al.
PLOS PATHOGENS (2010)
In Vitro and In Vivo Studies Identify Important Features of Dengue Virus pr-E Protein Interactions
Aihua Zheng et al.
PLOS PATHOGENS (2010)
Molecular evolution of dengue viruses: Contributions of phylogenetics to understanding the history and epidemiology of the preeminent arboviral disease
Scott C. Weaver et al.
INFECTION GENETICS AND EVOLUTION (2009)
Development of a novel DNA SynCon (TM) tetravalent dengue vaccine that elicits immune responses against four serotypes
Mathura P. Ramanathan et al.
VACCINE (2009)
Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III
Kiyohiko Matsui et al.
VIROLOGY (2009)
Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody
W. M. P. B. Wahala et al.
VIROLOGY (2009)
A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge
Sergio Oliveira De Paula et al.
ARCHIVES OF VIROLOGY (2008)
In vivo site-specific biotinylation of proteins within the secretory pathway using a single vector system
Andrea Predonzani et al.
BMC BIOTECHNOLOGY (2008)
Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: Implications for vaccine development
Theodore C. Pierson et al.
CELL HOST & MICROBE (2008)
Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus
Gregory D. Gromowski et al.
JOURNAL OF VIROLOGY (2008)
Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins
Shee-Mei Lok et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2008)
The flavivirus precursor membrane-envelope protein complex: Structure and maturation
Long Li et al.
SCIENCE (2008)
A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial
Julie E. Martin et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine
Barney S. Graham et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial
Julie E. Martin et al.
CLINICAL AND VACCINE IMMUNOLOGY (2006)
Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors
Saima Khanam et al.
VACCINE (2006)
A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypeg in rhesus macaques
Kanakatte Raviprakash et al.
VIROLOGY (2006)
Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice
E Konishi et al.
VACCINE (2006)
Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen
D Apt et al.
VACCINE (2006)
B lymphocytes participate in cross-presentation of antigen following gene gun vaccination
H Hon et al.
JOURNAL OF IMMUNOLOGY (2005)
BCL1 lymphoma protection induced by idiotype DNA vaccination is entirely dependent on anti-idiotypic antibodies
M Cesco-Gaspere et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
A structural perspective of the Flavivirus life cycle
S Mukhopadhyay et al.
NATURE REVIEWS MICROBIOLOGY (2005)
Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein
Y Modis et al.
JOURNAL OF VIROLOGY (2005)
Use of an immunoglobulin G avidity test to discriminate between primary and secondary dengue virus infections
VAUF de Souza et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2004)
Conformational changes of the flavivirus E glycoprotein
Y Zhang et al.
STRUCTURE (2004)
Class I and class II viral fusion protein structures reveal similar principles in membrane fusion (Review)
DJ Schibli et al.
MOLECULAR MEMBRANE BIOLOGY (2004)
Visualization of membrane protein domains by cryo-electron microscopy of dengue virus
W Zhang et al.
NATURE STRUCTURAL BIOLOGY (2003)
Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: Relevance to development and safety testing of live, attenuated vaccines
TP Monath et al.
JOURNAL OF VIROLOGY (2002)
Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF
K Raviprakash et al.
VIROLOGY (2001)
Anti-idiotypic antibodies induced by genetic immunisation are directed exclusively against combined VL/VH determinants
F Benvenuti et al.
GENE THERAPY (2001)
Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells
WD Crill et al.
JOURNAL OF VIROLOGY (2001)
Mutational evidence for an internal fusion peptide in flavivirus envelope protein E
SL Allison et al.
JOURNAL OF VIROLOGY (2001)
Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein
K Raviprakash et al.
VACCINE (2000)
Share Paper
